Taken together, the results from this study demonstrate that NRF2 induction by AIMs does not increase cellular proliferation or survival and that the downstream effects of pharmacological KEAP1 inhibition by AIMs are distinct from those that result from the loss of functional KEAP1 in tumor cells. Here, NFE2L2 is linked to neoplasm.